Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
PDS Biotechnology Corporation (NASDAQ: PDSB) closed the day trading at $0.77 down -4.15% from the previous closing price of $0.8. In other words, the price has decreased by -$4.15 from its previous closing price. On the day, 0.64 million shares were traded. PDSB stock price reached its highest trading level at $0.8094 during the session, while it also had its lowest trading level at $0.762.
Ratios:
For a better understanding of PDSB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.09 and its Current Ratio is at 2.09. In the meantime, Its Debt-to-Equity ratio is 1.90 whereas as Long-Term Debt/Eq ratio is at 1.26.
Upgrades & Downgrades
In the most recent recommendation for this company, B. Riley Securities on November 01, 2022, initiated with a Buy rating and assigned the stock a target price of $10.
On June 28, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.
H.C. Wainwright Upgraded its Neutral to Buy on November 10, 2020, while the target price for the stock was maintained at $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 28 ’25 when Freitag Gregory Gene bought 15,060 shares for $1.66 per share. The transaction valued at 25,000 led to the insider holds 61,213 shares of the business.
Glover Stephen C. bought 15,061 shares of PDSB for $25,001 on Feb 28 ’25. The Director now owns 78,851 shares after completing the transaction at $1.66 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PDSB now has a Market Capitalization of 42124464 and an Enterprise Value of 29473362.
Stock Price History:
The Beta on a monthly basis for PDSB is 1.11, which has changed by -0.57222223 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, PDSB has reached a high of $2.20, while it has fallen to a 52-week low of $0.70. The 50-Day Moving Average of the stock is -12.72%, while the 200-Day Moving Average is calculated to be -33.13%.
Shares Statistics:
Over the past 3-months, PDSB traded about 783.23K shares per day on average, while over the past 10 days, PDSB traded about 455740 shares per day. A total of 54.72M shares are outstanding, with a floating share count of 53.31M. Insiders hold about 2.58% of the company’s shares, while institutions hold 10.30% stake in the company. Shares short for PDSB as of 1765756800 were 1595913 with a Short Ratio of 2.04, compared to 1763078400 on 1639246. Therefore, it implies a Short% of Shares Outstanding of 1595913 and a Short% of Float of 2.9899999999999998.
Earnings Estimates
. The current market rating for PDS Biotechnology Corporation (PDSB) reflects the collective analysis of 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.18 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.8 and -$0.8 for the fiscal current year, implying an average EPS of -$0.8. EPS for the following year is -$0.68, with 3.0 analysts recommending between -$0.61 and -$0.73.
